Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

ClinicalTrials.gov ID: NCT02957682

Public ClinicalTrials.gov record NCT02957682. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.

Study identification

NCT ID
NCT02957682
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
2,176 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
40 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 1, 2016
Primary completion
Mar 4, 2020
Completion
Mar 4, 2020
Last update posted
May 6, 2021

2016 – 2020

United States locations

U.S. sites
73
U.S. states
26
U.S. cities
66
Facility City State ZIP Site status
Regeneron Study Site Auburn Alabama 36830
Regeneron Study Site Birmingham Alabama 35209
Regeneron Study Site Mobile Alabama 36608
Regeneron Study Site Beverly Hills California 90210
Regeneron Study Site Los Gatos California 95032
Regeneron Study Site North Hollywood California 91606
Regeneron Study Site Port Hueneme California 93041
Regeneron Study Site Westminster California 92683
Regeneron Study Site 1 Aurora Colorado 80012
Regeneron Study Site 2 Aurora Colorado 80012
Regeneron Study Site Colorado Springs Colorado 80906
Regeneron Study Site Lake Worth Florida 33461
Regeneron Study Site Lake Worth Florida 33462
Regeneron Study Site Miami Springs Florida 33166
Regeneron Study Site Covington Georgia 30014
Regeneron Study Site Champaign Illinois 61822
Regeneron Study Site Chicago Illinois 60602
Regeneron Study Site Chicago Illinois 60640
Regeneron Study Site Rock Island Illinois 61201
Regeneron Study Site Evansville Indiana 47714
Regeneron Study Site Indianapolis Indiana 46237
Regeneron Study Site Ames Iowa 50010-3014
Regeneron Study Site Iowa City Iowa 52242
Regeneron Study Site Waterloo Iowa 50702
Regeneron Study Site Hutchinson Kansas 67502
Regeneron Study Site Newton Kansas 67114
Regeneron Study Site Overland Park Kansas 66209
Regeneron Study Site Louisville Kentucky 40213
Regeneron Study Site Bangor Maine 04401
Regeneron Study Site Baltimore Maryland 21229
Regeneron Study Site Oxon Hill Maryland 20745
Regeneron Study Site Minneapolis Minnesota 55407
Regeneron Study Site Olive Branch Mississippi 38654
Regeneron Study Site Washington Missouri 63090
Regeneron Study Site Buffalo New York 14215
Regeneron Study Site New Hyde Park New York 11042
Regeneron Study Site Cary North Carolina 27518
Regeneron Study Site Charlotte North Carolina 28209
Regeneron Study Site Charlotte North Carolina 28277
Regeneron Study Site Greensboro North Carolina 27401
Regeneron Study Site Hickory North Carolina 28601
Regeneron Study Site High Point North Carolina 27262
Regeneron Study Site Raleigh North Carolina 27609
Regeneron Study Site Rocky Mount North Carolina 27804
Regeneron Study Site Salisbury North Carolina 28144
Regeneron Study Site Statesville North Carolina 28625
Regeneron Study Site Wilmington North Carolina 28401
Regeneron Study Site Winston-Salem North Carolina 27103
Regeneron Study Site Cincinnati Ohio 45219
Regeneron Study Site Cleveland Ohio 44122
Regeneron Study Site Dayton Ohio 45414
Regeneron Study Site Duncansville Pennsylvania 16635
Regeneron Study Site Charleston South Carolina 29407
Regeneron Study Site Greenville South Carolina 29485
Regeneron Study Site Summerville South Carolina 29615
Regeneron Study Site Rapid City South Dakota 57701
Regeneron Study Site Bristol Tennessee 37620
Regeneron Study Site Knoxville Tennessee 37760
Regeneron Study Site Knoxville Tennessee 37912
Regeneron Study Site Knoxville Tennessee 37938
Regeneron Study Site Powell Tennessee 37849
Regeneron Study Site Dallas Texas 75231
Regeneron Study Site Houston Texas 77002
Regeneron Study Site Houston Texas 77027
Regeneron Study Site Schertz Texas 78154
Regeneron Study Site Shavano Park Texas 78231
Regeneron Study Site Falls Church Virginia 22601
Regeneron Study Site Winchester Virginia 22042
Regeneron Study Site Burien Washington 98166
Regeneron Study Site Everett Washington 98405
Regeneron Study Site Tacoma Washington 98405
Regeneron Study Site Walla Walla Washington 99362
Regeneron Study Site Manitowoc Wisconsin 54220

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 115 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02957682, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 6, 2021 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02957682 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →